Our Mission

The Ataxia Charlevoix-Saguenay Foundation’s mission is to discover and develop a treatment for the Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).

Persons with ARSACS

You have been diagnosed with ARSACS, you are not alone. Individuals living with ARSACS are all around the world.

There is hope because Research that heals!

Researchers

Interested in doing ARSACS research ?

The Foundation supports ARSACS researchers by providing funding, research tools and supporting/ organizing conferences.

Furthermore, the Foundation is looking for partners to conduct preclinical and clinical trials.

Community

The Foundation is supported entirely by private donors and volunteers. We need your support to pursue the mission. 

Different ways you can help. Get involved. 

Your voice is very important. Make your voice heard by participating in ARSACS research. 

Connect with Other ARSACS Patients

ARSACS International Patient Registry

Researchers & Pharmaceuticals

Apply for a grant

 The Foundation provides grants and opportunities to researchers.The research grant could be as high as $100,000 for a 12 month period and could be renewed for a second year.

Research tools available

  • Sacs Knock Out mouse (#033221)
  • Sacs Knock In mouse (#033385)
  • iPS cells derived from samples taken from people diagnosed with ARSACS (homozygous c.8844delT). 

 

Conferences

The Foundation organizes and supports conferences such as the International ARSACS Symposium.

Preclinical and clinical trials

The Foundation is looking for partners  to conduct preclinical and clinical trials. It has the expertise and the tools available.

What can I do to help the ARSACS community and the ARSACS Foundation?

ARSACS is a rare disease. You can help by becoming an ARSACS advocate and creating awareness for the cause.

You can organize fundraising activities in your community to support research and clinical trials.

Another way to help ….  Be the eyes on what is going on. You do not have to be a scientist to help advance science for ARSACS. We believe that research on other neurological diseases may help research on ARSACS and eventually lead to therapies. This is the reason why we asked you to be the eyes on what is going on for other types of ataxias and other neurological diseases. In other words, if you see or read scientific material that is worth sharing and validating (outbreaks, drugs, clinical trials, fundamental research developments), please do not hesitate to transmit this information to the ARSACS Foundation. The Foundation has dedicated volunteers and can seek professional advice to confirm or infirm the relevance of the information with respect to ARSACS.

The Ataxia Charlevoix-Saguenay Foundation’s mission is to discover and develop a treatment for the Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).

The Ataxia Charlevoix-Saguenay Foundation, founded in 2006, is a charitable organization federally registered with no employees and is supported entirely by private donations and volunteers 

Research that heals so

There is HOPE

The Foundation’s mission is to discover and develop a treatment for the Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS).

Progress has been made over the years in identifying the source of the disorder. Your support is crucial to continue funding high potential projects as well as a clinical trial of a repurposed drug.

Latest News

ARSACS research featured on CBC Radio

ARSACS research featured on CBC Radio

ARSACS research project, led by Drs. Mckinney ,Watt and Toscano- Marquez, was featured on CBC radio “Let’s Go” on 2022-01-20. As part of the “Understanding the Brain” segment, Rackeb Tesfaye, science columnist at CBC radio and a PHD candidate in neurosciences, provided an overview of ARSACS history and explained the latest discovery made by the McGill research team. “Let Go”

$1.250M net raised for ARSACS research  at the Diner des Producteurs

$1.250M net raised for ARSACS research at the Diner des Producteurs

  ” To all of you : Mr. Marc Bédard, Honorary President, sponsors, partners, donors and volunteers, it is thanks to you that the Foundation can pursue it’s mission. Thank you! ” Jean Groleau , president of the Ataxia Charlevoix-Saguenay Foundation. The Diner des Producteurs, a major fundraising event for the Foundation, was held in Montreal on December 6, 2021.

McGill ARSACS researchers team made a surprising discovery: not all zebrin-negative cells behave the same

McGill ARSACS researchers team made a surprising discovery: not all zebrin-negative cells behave the same

Latest news release from McGill University, Montreal- Researchers at McGill University, lead by Drs. Alanna Watt and Anne Mckinney, have made an important step forward in understanding the cause of ARSACS. “We have shown really clearly that zebrin-negative cells in the posterior vermis were not degenerating,” Watt says. “We did not expect that. We thought eventually zebrin-negative cells in all parts of the vermis would succumb, but it’s just not what we see.” Welcome news for families affected by ARSACS. Research published in Frontiers in Cellular Neuroscience.

Dr. Pandolfo joins the Foundation’s Board

Dr. Pandolfo joins the Foundation’s Board

The Ataxia Charlevoix-Saguenay Foundation is pleased to announce that Dr. Massimo Pandolfo has joined its board of directors. Dr. Pandolfo is Professor of Neurology at McGill University in Montreal since January 2021. Prior, he was Professor of neurology and Director of the Laboratory of Experimental Neurology at the Université Libre de Bruxelles in Belgium.

“Our Board is fortunate to benefit from Dr. Pandolfo’s vast experience on ataxias. His expertise in clinical and genetic study of several rare neurological diseases will be very helpful to pursue our mission” said Jean Groleau, president of the Foundation.

Me Jean Groleau named Vice-President of Catalis Board of Directors

Me Jean Groleau named Vice-President of Catalis Board of Directors

Me Jean Groleau, co-founder and president of the Fondation de l’Ataxie Charlevoix-Saguenay, is proud to join Catalis to represent the needs and challenges of people with rare diseases. Launched in 2017, CATALIS’ mandate is, among other things, to facilitate collaboration between the various actors and to accelerate the development of innovative treatments.